|
Jun 4
|
PAVmed subsidiary Veris Health partners with Ohio State University cancer center
|
|
Jun 3
|
PAVmed Subsidiary, Veris Health, Enters into Strategic Partnership Agreement with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
|
|
May 27
|
Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes
|
|
May 16
|
PAVmed Inc (PAVM) Q1 2025 Earnings Call Highlights: Strategic Expansion and Financial Fortification
|
|
May 15
|
PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results
|
|
May 14
|
Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results
|
|
Oct 10
|
PAVmed Subsidiary, Veris Health, Awarded $1.8 Million NIH Grant to Enhance Cancer Care
|
|
Oct 9
|
Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit
|
|
Oct 8
|
Lucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024
|
|
Oct 1
|
Lucid Diagnostics Holds Inaugural #CheckYourFoodTube Precancer Testing Event for Former NFL Players
|
|
Sep 3
|
Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health
|
|
Jul 30
|
PAVmed to Hold a Business Update Conference Call and Webcast on August 13, 2024
|
|
Jul 29
|
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 12, 2024
|
|
Jul 23
|
Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume
|
|
Jun 13
|
PAVmed Subsidiary, Veris Health, Announces Launch of Pilot Program with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
|
|
May 15
|
PAVmed Inc (PAVM) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth and Financial ...
|
|
May 15
|
Q1 2024 PAVmed Inc Earnings Call
|
|
May 14
|
PAVmed Provides Business Update and First Quarter 2024 Financial Results
|
|
May 13
|
Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial Results
|
|
May 9
|
Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall
|